Vedolizumab as induction and maintenance therapy for Crohn's disease
Loading...
Date
Authors
Sandborn, William J.
Feagan, Brian G.
Rutgeerts, Paul
Hanauer, Stephen
Colombel, Jean-Frédéric
Sands, Bruce E.
Lucas, Milan
Fedorak, Richard N.
Lee, Scott
Bressler, Brian
Journal Title
Journal ISSN
Volume Title
Publisher
Massachusetts Medical Society
Abstract
BACKGROUND: The efficacy of vedolizumab, an α4β 7 integrin antibody, in Crohn's disease is unknown. METHODS: In an integrated study with separate induction and maintenance trials, we assessed intravenous vedolizumab therapy (300 mg) in adults with activ
Description
Citation
Collections
Source
New England Journal of Medicine
Type
Book Title
Entity type
Access Statement
License Rights
Restricted until
2037-12-31